Cases reports: Unintended anti‐doping rule violation after dorzolamide use several months prior to a doping control. Issue 10 (30th August 2021)

• Record Type: Journal Article
• Authors: Pokrywka, Andrzej; Skrzypiec‐Spring, Monika; Krzywański, Jarosław; Rynkowski, Michał; Saugy, Martial; Faiss, Raphael
• Is Part Of: Drug testing and analysis. Volume 13:Issue 10(2021)
• Page Start: 1803
• Page End: 1806
• Publication Date: 2021-08-30
• Subjects: dorzolamide -- eye drops -- unintended doping; Drugs -- Analysis -- Periodicals; Drug testing -- Periodicals; Chemistry, Forensic -- Periodicals; 615.1901
• DOI: 10.1002/dta.3156
• Languages: English
• ISSNs: 1942-7603

Abstract

Abstract : The use of specific medicine up to several months before a doping control is not be reported on the doping control form, while the drug could then still be detectable in urine in case of a very slow elimination. It may lead to a positive test result. For example, dorzolamide, a carbonic anhydrase inhibitor for topical ophthalmic application, has a very slow elimination rate via the renal route (half‐life > 4 months). This substance can be a source of unintended anti‐doping rule violations.